rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    WVE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Wave Life Sciences at Jefferies Global Healthcare Conference: obesity push
      12h agoInvesting.comWVEJEF
      Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
      Nov 11Yahoo FinanceWVE
      Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout (WVE)
      Nov 10Seeking AlphaWVE
      Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation - Slideshow
      Nov 10Seeking AlphaWVE
      Wave: 3 Key Takeaways for Long-Term Investors
      Nov 8Yahoo FinanceWVE
      WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
      Nov 4Yahoo FinanceWVE
      Wave Life Sciences (WVE) Stock Rallies As Q3 Results Ease Loss Fears
      Oct 28Yahoo FinanceWVE
      Oppenheimer cuts Wave Life Sciences stock price target on model update
      Oct 28Investing.comWVE
      Wave Life Sciences Ltd. Q3 2026 Earnings Call Summary
      Oct 28Yahoo FinanceWVE
      Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 27The Globe and MailWVE
      WAVE Life Sciences Q3 Earnings Call Highlights
      Oct 27Yahoo FinanceWVE
      Wave Life Sciences Ltd earnings beat by $0.02, revenue topped estimates
      Oct 27Investing.comWVE
      Earnings call transcript: Wave Life Sciences tops Q3 2026 forecasts on revenue
      Oct 27Investing.comWVE
      Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

      Wave Life Sciences (WVE) delivered earnings and revenue surprises of +11.77% and +342.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Oct 27Yahoo FinanceWVE
      Wave Life Sciences: Q3 Earnings Snapshot
      Oct 27Yahoo FinanceWVE
      Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
      Oct 27Yahoo FinanceWVE
      WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
      Oct 22Yahoo FinanceWVE
      Wave Life Sciences at Chardan’s 10th Annual Healthcare Conference: chemistry focus
      Oct 20Investing.comWVE
      Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
      Oct 20Yahoo FinanceWVE
      Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
      Oct 19Yahoo FinanceWVE
      Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views
      Oct 17Yahoo FinanceWVE
      William Blair initiates Wave Life Sciences stock with outperform rating
      Oct 16Investing.comWVE
      UBS Initiates Wave Life Sciences at Buy With $11 Price Target
      Oct 15Yahoo FinanceWVE
      Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Liquidia Technologies (LQDA) and Abbott Laboratories (ABT)

      Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailWVE
      Analysts Offer Insights on Healthcare Companies: Cigna (CI), Wave Life Sciences (WVE) and Regeneron (REGN)

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailWVE
      H.C. Wainwright reiterates Buy on Wave Life Sciences stock
      Oct 2Investing.comWVE
      Wave Life, FDA agree on plans for AATD therapy (WVE:NASDAQ)

      Wave Life Sciences (WVE) stock jumps as the FDA backs a registrational pathway for WVE-006, a treatment for alpha-1 antitrypsin deficiency. Read more here.

      Oct 1Seeking AlphaWVE
      Wave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006
      Oct 1Yahoo FinanceWVE
      Wave Life Sciences reaches FDA alignment on WVE-006 trial design
      Oct 1Investing.comWVE
      Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

      Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad

      Oct 1Yahoo FinanceWVE
      Ladenburg Thalmann Initiates Wave Life Sciences at Buy With $10 Price Target

      Wave Life Sciences (WVE) has an average rating of buy and mean price target of $19.94, according to

      Oct 1Yahoo FinanceACHVWVE
      Wave to receive $12M milestone from GSK (WVE:NASDAQ)
      Sep 30Seeking AlphaWVEGSK
      GSK selects Wave Life Sciences hepatology candidate
      Sep 30Investing.comWVE
      Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

      Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology

      Sep 30Yahoo FinanceWVEGSK
      Stifel Initiates Achieve Life Sciences at Buy With $18 Price Target
      Sep 30Yahoo FinanceACHVWVE
      Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug

      Wave Life Sciences (WVE) said Wednesday that GSK (GSK) selected a liver disease drug candidate from

      Sep 30Yahoo FinanceWVE
      Wave Life Sciences starts Phase 2a obesity trial for WVE-007
      Sep 23Investing.comWVE
      JPMorgan resumes Wave Life Sciences stock rating at Neutral
      Sep 23Investing.comWVE
      Wave Life Sciences appoints Monika Vnuk as chief business officer
      Sep 22Investing.comWVE
      Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

      Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate de

      Sep 22Yahoo FinanceWVE
      Wave Life Sciences at Cantor conference: RNA editing gains traction
      Sep 10Investing.comWVE
      Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

      CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present

      Sep 3Yahoo FinanceWVE

      This is the newest page. Registered accounts read further back.